MARKET

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.49
0.00
0.00%
Closed 16:00 08/14 EDT
OPEN
--
PREV CLOSE
5.63
HIGH
--
LOW
--
VOLUME
10
TURNOVER
--
52 WEEK HIGH
8.07
52 WEEK LOW
3.870
MARKET CAP
2.18M
P/E (TTM)
-0.7535
1D
5D
1M
3M
1Y
5Y

CYCCP News

More
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second
GlobeNewswire · 08/05 11:00
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Zacks · 07/28 15:46
Cyclacel's Highlights Publication Of Peer-Reviewed Study Of Clinical Stage CDK2/9 Inhibitor Fadraciclib
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on
Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on · 07/13 11:05
3 Strong Buy Biotech Stocks Under $5 With Massive Upside Potential
TipRanks · 05/21 14:22
UNFI, SDC among premarket gainers
Seeking Alpha - Article · 05/13 13:12
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 03:05
Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results
GlobeNewswire · 05/12 21:05
Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results
GlobeNewswire · 05/05 12:00

Industry

Biotechnology & Medical Research
-0.54%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About CYCCP

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
More

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.